Pharma regulators around the globe have different approaches to ensure companies meet drug safety laws and standards. Examining statistics on recent inspections gives insight into the common ...

In this article, Marty Nicholas provides us with three quick-win, pharma-specific Sales Force Effectiveness strategies that drive an immediate lift in sales performance. To many sales leaders, the ...

Cate Evans, SVP group director, strategy at Havas Media Group, and Nick Lapolla, research director at MedSurvey tell us about a two-phase research study the companies recently performed to ...

A digital health application (DiGA) has been shown to relieve the distress that patients can experience when managing diabetes, which can compromise their care, in a randomised clinical trial.

The use of specialty drugs in the U.S. has skyrocketed in recent years driven primarily by an increase in chronic condition diagnosis and the number of new medications on the market. Krishnanjan ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Engaging, strategic, customer-centric communication is important in any industry, and no industry has been unaffected by the changing world of digital communication. But healthcare communicators ...

NHS England has awarded a new contract to US data analytics company Palantir to transition existing NHS projects into a new federated data platform (FDP), prompting pushback from organisations ...

Are you looking to solve challenges with current RNA therapeutics, such as the degradation of RNA by RNAses, the difficulty of RNA crossing the cell membrane by diffusion and the immunogenicity ...

It is easy to be distracted by the latest revolutionary therapy and miss the broader revolutions which proceed more slowly but also change the industry more fundamentally. Two such revolutions ...

Shares in Neurocrine Biosciences took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...